Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive PDT + Aflibercept for Persistent NV AMD
NCT02457026Withdrawn
- Sponsor
- Duke University
- Start
- Jan 2016
- Primary completion
- Jan 2018
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Randomised, open-label trial of verteporfin in neovascular age-related macular degeneration (NVAMD), sponsored by Duke University. Planned start Jan 2016; status: withdrawn.
02
Drugs
verteporfin
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02457026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02457026.